Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells

Cancer Research

Volumn 71, Issue 5, 2011, Pages 1956-1967

  Östling, Päivi ^a,b,c   Leivonen, Suvi Katri ^a,b,c   Aakula, Anna ^a,b,c   Kohonen, Pekka ^a,b,c   Mäkelä, Rami ^a,b,c   Hagman, Zandra ^d   Edsjö, Anders ^d,e   Kangaspeska, Sara ^f   Edgren, Henrik ^f   Nicorici, Daniel ^f   Bjartell, Anders ^d   Ceder, Yvonne ^d   Perälä, Merja ^a,b,c   Kallioniemi, Olli ^a,b,c,f  

^a VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c ÅBO AKADEMI UNIVERSITY   (Finland)

^d LUND UNIVERSITY   (Sweden)

^e Lund University   (Sweden)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; MICRORNA;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; GENE IDENTIFICATION; GENETIC SCREENING; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; MOLECULAR INTERACTION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; RNA BINDING; RNA SEQUENCE; TRANSCRIPTION REGULATION;

EID: 79952205258     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2421     Document Type: Article

References (44)

1. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27. (Pubitemid 38364606)
2. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25(2):276-308. (Pubitemid 38501396)
3. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8:440-8.
4. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45. (Pubitemid 33741879)
5. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995;55:3068-72.
6. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9. (Pubitemid 38524696)
7. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010;17:443-54.
8. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009;138:245-56.
9. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-31. (Pubitemid 38868508)
10. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
11. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
12. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
13. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66. (Pubitemid 44629897)
14. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010;10(6):389-402.
15. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009;27:5848-56.
16. Gandellini P, Folini M, Zaffaroni N. Towards the definition of prostate cancer-related microRNAs: where are we now?Trends Mol Med 2009;15:381-90.
17. Hagman Z, Larne O, Edsjo A, Bjartell A, Ehrnström RA, Ulmert D, et al. miR-34c is down regulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 2010;127:2768-76.
18. Leivonen SK, Makela R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, et al. Protein lysatemicroarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene 2009;28:3926-36.
19. Boutros M, Bras LP, Huber W. Analysis of cell-based RNAi screens. Genome Biol 2006;7:R66.1-11.
20. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL, Chory J. RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 2006;22:2825-7. (Pubitemid 44742407)
21. Durinck S, Bullard J, Spellman PT, Dudoit S. GenomeGraphs: integrated genomic data visualization with R. BMC Bioinformatics 2009;6(10):1-9.
22. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002;18Suppl 1:S96-104.
23. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res 2008;36:D149-53.
24. Trapman J, Klaassen P, Kuiper GG, van der Korput JA, Faber PW, van Rooij HC, et al. Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun 1988;153:241-8.
25. Lubahn DB, Joseph DR, Sar M, Tan J, Higgs HN, Larson RE, et al. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 1988;2:1265-75. (Pubitemid 19005939)
26. Korenchuck S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, et al. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001;(15):163-63
27. Makkonen H, Kauhanen M, Jääskeläinen T, Palvimo JJ. Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells. Mol Cell Endocrinol 2010; in press doi:10.1016
28. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009;69:2305-13.
29. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68:5469-77.
30. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21. (Pubitemid 32397092)
31. Sikand K, Slaibi JE, Singh R, Slane SD, Shukla GC. miR 488* inhibits androgen receptor expression in prostate carcinoma cells. Int J Cancer 2010, in press, doi 10.1002/ijc.25753
32. Grey F, Tirabassi R, Meyers H, Wu G, McWeeney S, Hook L, et al. A viral microRNA down-regulates multiple cell cycle genes through mRNA 5′UTRs. PLoS Pathog 2010;6:e1000967.1-9.
33. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR. Proc Natl Acad Sci U S A 2007;104:9667-72. (Pubitemid 47175324)
34. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008;30:460-71. (Pubitemid 351672378)
35. Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, Kim NH, et al. New class of microRNA targets containing simultaneous 5′-UTR and 3′-UTR interaction sites. Genome Res 2009;19:1175-83.
36. Spizzo R, Nicoloso MS, Lupini L, et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 2010;17:246-54.
37. Mangone M, Manoharan AP, Thierry-Mieg D, Thierry-Mieg J, Han T, Mackowiak SD, et al. The landscape of C. elegans 3′UTRs. Science 2010;329:432-5.
38. Wu S, Huang S, Ding J, Zhao Y, Liang L, Liu T, et al. Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3′ untranslated region. Oncogene 2010;29:2302-8.
39. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010;17:193-9.
40. Hermeking H. p53 enters the microRNA world. Cancer Cell 2007;12:414-8.
41. Huggins C, Hodges CV. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prosate. 1941;1:293-7.
42. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28:1481-8.
43. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC , et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28:1489-95.
44. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.